Home Archives July 2008 State wins case against Merck

State wins case against Merck

| Print |  Email
Tuesday, July 01, 2008

STATEWIDE Oregon’s lead role in a record-breaking settlement with Merck & Co. over deceptive marketing for the anti-inflammatory drug Vioxx represents the latest skirmish in an ongoing campaign against Big Pharma that has earned the state more than $8.5 million.

After leading a three-year, 30-state investigation into deceptive advertisements downplaying the health risks associated with Vioxx, Oregon received $2.8 million of the record $58 million paid out by Merck. The judgment banned Merck from manipulating data when marketing to physicians, “ghost writing” articles for medical journals and failing to disclose conflicts of interest among doctors who study and promote drugs on behalf of the company.

The Vioxx settlement reflects growing concerns over how drug companies hook consumers on prescription drugs. Drug giants have poured billions into “demand creation” since the federal government loosened rules prohibiting “direct-to-consumer” advertising in 1997. In 2007 Oregon was the lead state in an $8 million settlement against Bayer for minimizing the dangers of Baycol, and also was in on a $19.5 million settlement against Purdue Pharma regarding OxyContin.

State officials cannot comment about current cases involving major pharmaceutical firms, but Oregon’s campaign against Big Pharma is clearly far from finished. Leading the way has been assistant attorney general David Hart, who worked in health care prior to pursuing consumer law and is married to a pharmacist. Hart has served as lead investigator and negotiator on all of Oregon’s major drug company cases. “The money we’ve gotten in these settlements gets put to good use, but these cases aren’t about the money,” he says, “they’re about the rules we create and the light that we shed on these practices so that we can change them.”

Ken Johnson, vice president of the Pharmaceutical Research and Manufacturers of America, said in a prepared statement that drug companies “are committed to providing accurate, educational information to patients and health professionals about their medicines.”


BEN JACKLET


To comment, email This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

 

More Articles

Private liberal arts education: superior outcomes, competitive price

Contributed Blogs
Tuesday, August 26, 2014
0826 thumb collegemoneyBY DEBRA RINGOLD | OP-ED CONTRIBUTOR

Why has six years become an acceptable investment in public undergraduate education that over-promises and underperforms?


Read more...

Podcast: Interview with Steve Balzac

Contributed Blogs
Tuesday, August 19, 2014

082014BalzacBY TOM COX | OB BLOGGER

Tom Cox interviews Steve Balzac, author of "Organizational Psychology for Managers."


Read more...

Back to School

September 2014
Wednesday, August 27, 2014
BY LEE VAN DER VOO

By now we’ve all read the headlines: Starbucks is giving away free degrees. Except it isn’t.


Read more...

Downtime

September 2014
Wednesday, August 27, 2014
BY JESSICA RIDGWAY

How State Representative Julie Parrish (House District 37) balances life between work and play.


Read more...

Podcast: Interview with Pete Friedes

Contributed Blogs
Wednesday, August 27, 2014

082714-thumb friedesbookTom Cox interviews Pete Friedes, author of "The 2R Manager," about becoming a Best Boss.


Read more...

Molecular Movies

September 2014
Wednesday, August 27, 2014
BY LINDA BAKER

Dr. Chong Fang isn’t God. But the assistant professor of chemistry at Oregon State University is getting closer to figuring out how he put everything together. 


Read more...

Is this employee right?

Contributed Blogs
Wednesday, August 13, 2014
081314 thumb employeefeelingsBY TOM COX | OB BLOGGER

When I say, “Your Employee is Always Right,” I do not mean “right about the facts,” but rather “right about how they feel” and “right about how they want to be led.”


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS